CD8A and COVID-19: Our immunological data suggest that a heterologous vector-based/mRNA prime-boost schedule would be highly effective in preventing COVID-19, as neutralizing antibody levels correlate with immune protection from symptomatic SARS-CoV-2 infection41 and CD8+ T cell responses have been associated with a mild disease course.42